Landmark, pivotal Phase IIb/III trial of biotoxin for cancer p...( Investigators involved in the pivotal c...)

Investigators involved in the pivotal clinical trial of Tectin^TM enrolled and dosed the first of up to 150 patients that will participate in the study. It is one of the largest Canadian clinical trials to evaluate the efficacy and safety of a drug for treatment of medically refractory cancer pain, and will take place in up to 25 treatment centres across Canada.

Tectin, a drug derived from the puffer fish, also known as blow fish or fugu, has been developed by Vancouver-based International Wex Technologies Inc. to block slow sodium channel nocicipetive pain fibers in a highly selective manner. Results from a recently completed open-label Phase IIa dose were presented in a podium presentation by the lead investigator, Dr. Neil Hagen, during the 2nd Joint Scientific Meeting of the American Pain Society and the Canadian Pain Society that was held in Vancouver, B.C, on May 6-9, 2004.

The Phase IIa results demonstrate that Tectin^TM, administered intramuscularly for four days at the studied doses, is well tolerated and can relieve refractory cancer pain for up to two weeks in some patients. Consistent with the interim analysis, the final results show that almost three-quarters (72%) of cancer pain patients experienced a clinically meaningful analgesic response.

Based on these promising results, the Company was encouraged to pursue a larger trial to further confirm the effectiveness of the compound. The current trial is a multicentre, randomized, double-blind and placebo-controlled study designed to compare the efficacy and safety of Tectin^TM versus placebo in moderate to severe inadequately controlled cancer-related pain.

The study is being led by two nationally respected leaders in cancer pain assessment and management, Dr. Neil Hagen, Head of the Division of Palliative Medicine, Department of Oncology at the University of Calgary and Dr. Bernard Lapointe, Chief of the Palliative Care Division of the Je
'"/>

Contact: Don Evans
don@wextech.ca
604-683-8880
WEX Pharmaceuticals Inc.
11-May-2004

Page: 1 2
Related biology news :

1. Results of pivotal study for GlaxoSmithKlines Valtrex published in New England Journal of Medicine
2. ENBREL provided rapid and significant relief for psoriasis patients in second pivotal study
3. UCSF-led study points to pivotal, early event in cancer development
4. Final results of the two Zevalin pivotal trials in radioimmunotherapy for B cell Non-Hodgkins Lymphoma announced by IDEC Pharmaceuticals
5. BRCA1 cancer gene plays pivotal role in DNA control complex
6. PRAECIS announces positive results for abarelix depot-M in two pivotal Phase III clinical trials
7. Phase II trials of second-generation antisense cancer drug planned following successful early study
8. OneWorld Health completes enrollment, treatment in Phase III India trial
9. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
10. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
11. KEPPRA international Phase IV SKATE study results show favourable efficacy